Á
Ángel Díaz
Researcher at University of León
Publications - 22
Citations - 127
Ángel Díaz is an academic researcher from University of León. The author has contributed to research in topics: Steatohepatitis & Liver cancer. The author has an hindex of 6, co-authored 22 publications receiving 107 citations.
Papers
More filters
Journal ArticleDOI
Documento de consenso sobre el manejo de la dislipemia aterogénica de la Sociedad Española de Arteriosclerosis
Juan F. Ascaso,Jesús Millán,Antonio Hernández-Mijares,Mariano Blasco,Ángel Brea,Ángel Díaz,Teresa Mantilla,Juan Pedro-Botet,Xavier Pintó +8 more
TL;DR: The authors present a documento de posicionamiento y resumen de las recomendaciones recientemente publicadas by el Grupo de Trabajo de Dislipemia Aterogenica de la Sociedad Espanola de Arteriosclerosis and by the Sociedads Europea de ARTERIOMS.
Journal ArticleDOI
La auténtica dimensión del colesterol-no-HDL: colesterol aterogénico
Jesús Millán,Antonio Hernández-Mijares,Juan F. Ascaso,Mariano Blasco,Ángel Brea,Ángel Díaz,Pedro González-Santos,Teresa Mantilla,J. Pedro-Botet,Xavier Pintó +9 more
TL;DR: Non-HDL-cholesterol should be an excellent marker of atherogenic cholesterol, and an major therapeutic target in patients with Atherogenic dyslipidaemia, according to different clinical trials and with the epidemiological and mendelian studies.
Journal ArticleDOI
Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis.
Juan F. Ascaso,Jesús Millán,Antonio Hernández-Mijares,Mariano Blasco,Ángel Brea,Ángel Díaz,Teresa Mantilla,Juan Pedro-Botet,Xavier Pintó +8 more
TL;DR: Positioning document and summary of recommendations recently published by the Working Group on Atherogenic Dyslipemia and by the European Society of Arteriosclerosis.
Journal ArticleDOI
Enfermedad del hígado graso no alcohólico, asociación con la enfermedad cardiovascular y tratamiento (II). Tratamiento de la enfermedad del hígado graso no alcohólico
Ángel Brea,Xavier Pintó,Juan F. Ascaso,Mariano Blasco,Ángel Díaz,Pedro González-Santos,Antonio Hernández-Mijares,Teresa Mantilla,Jesús Millán,Juan Pedro-Botet +9 more
TL;DR: Durante la ultima decada se ha observado that the EHGNA da lugar a un incremento del riesgo cardiovascular con aceleracion of the arteriosclerosis and of los episodios cardiovasculares, principal causa of su morbimortalidad.
Journal ArticleDOI
Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects.
Antonio Hernández-Mijares,Juan F. Ascaso,Mariano Blasco,Ángel Brea,Ángel Díaz,Teresa Mantilla,Juan Pedro-Botet,Xavier Pintó,Jesús Millán +8 more
TL;DR: In terms of pharmacological treatment, fenofibrate seems to be effective in situations of atherogenic dyslipidemia, and there is no evidence of cardiovascular benefit with drugs aimed at lowering triglycerides and HDL-C, as well as the benefits of statin treatment.